Nilsine Partners LLC Decreases Stock Position in Zoetis Inc. $ZTS

Nilsine Partners LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 85.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,061 shares of the company’s stock after selling 29,215 shares during the quarter. Nilsine Partners LLC’s holdings in Zoetis were worth $637,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. CIBC Asset Management Inc increased its position in shares of Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after acquiring an additional 10,434 shares during the period. Mitsubishi UFJ Trust & Banking Corp lifted its position in Zoetis by 6.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after acquiring an additional 18,040 shares during the period. Quilter Plc lifted its position in Zoetis by 10.2% during the 3rd quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after acquiring an additional 40,615 shares during the period. Nordea Investment Management AB grew its stake in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Finally, Ninety One UK Ltd grew its stake in Zoetis by 19.6% during the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after purchasing an additional 183,686 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of several research analyst reports. Barclays assumed coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Bank of America lifted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Finally, The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Stock Performance

Shares of ZTS stock opened at $117.83 on Friday. The stock has a market cap of $49.74 billion, a PE ratio of 19.57, a price-to-earnings-growth ratio of 1.79 and a beta of 0.98. The business has a 50-day simple moving average of $122.84 and a 200-day simple moving average of $128.42. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 52-week low of $113.29 and a 52-week high of $172.23.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.